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Abstract 
Background: Bipolar disorder refers to a group of chronic psychiatric disorders of mood and energy levels. While dra-
matic psychiatric symptoms dominate the acute phase of the diseases, the chronic course is often determined by an 
increasing burden of co-occurring medical conditions. High rates of diabetes mellitus in patients with bipolar disorder 
are particularly striking, yet unexplained. Treatment and lifestyle factors could play a significant role, and some studies 
also suggest shared pathophysiology and risk factors.
Objective: In this systematic literature review, we explored data around the relationship between bipolar disorder 
and diabetes mellitus in recently published population-based cohort studies with special focus on the elderly.
Methods: A systematic search in the PubMed database for the combined terms “bipolar disorder” AND “elderly” AND 
“diabetes” in papers published between January 2009 and December 2015 revealed 117 publications; 7 studies were 
large cohort studies, and therefore, were included in our review.
Results: We found that age- and gender- adjusted risk for diabetes mellitus was increased in patients with bipolar 
disorder and vice versa (odds ratio range between 1.7 and 3.2).
Discussion: Our results in large population-based cohort studies are consistent with the results of smaller studies 
and chart reviews. Even though it is likely that heterogeneous risk factors may play a role in diabetes mellitus and in 
bipolar disorder, growing evidence from cell culture experiments and animal studies suggests shared disease mecha-
nisms. Furthermore, disease-modifying effects of bipolar disorder and diabetes mellitus on each other appear to be 
substantial, impacting both treatment response and outcomes.
Conclusions: The risk of diabetes mellitus in patients with bipolar disorder is increased. Our findings add to the 
growing literature on this topic. Increasing evidence for shared disease mechanisms suggests new disease models 
that could explain the results of our study. A better understanding of the complex relationship between bipolar disor-
der and diabetes mellitus could lead to novel therapeutic approaches and improved outcomes.
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Background
Bipolar disorder (BD) refers to a group of conditions that 
share the defining features of elated/euphoric or irritable 
mood accompanied by persistently increased activity or 
energy levels, also known as mania (American Psychiatric 
Association 2013). BD occurs worldwide with a lifetime 
prevalence of about 0.6 % for BD-I and 0.4 % for BD-II, 
with slightly higher rates reported in developed countries 
(Merikangas et al. 2007, 2011).
Evidence for an increase in chronic medical conditions 
in patients with BD has been described since the pre-
treatment era (Esquirol 1845; Swift 1907; Rennie 1942; 
Stenstedt 1952; Alvarez Ariza 2009). Several disorders 
are frequently diagnosed in patients with BD, includ-
ing epilepsy, thyroid disorders, cardiovascular diseases, 
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autoimmune–allergic disorders, and diabetes mellitus, 
especially in the elderly (Lala and Sajatovic 2012; Perugi 
et  al. 2015). Since symptoms of these somatic disorders 
overlap with those of BD, they could challenge the diag-
nostic process and delay treatment (Sajatovic and Chen 
2011; Smith et al. 2013; Maina et al. 2013). Chronic medi-
cal conditions in patients with severe mental illness also 
lead to increased risk of frequent hospitalizations and 
re-hospitalizations (Davydow et  al. 2015). While recent 
reviews of this topic have identified comorbid medi-
cal conditions in the elderly with BD as a growing pub-
lic health problem (Depp and Jeste 2004; Vasudev and 
Thomas 2010; Dols et  al. 2014; Sajatovic et  al. 2015a), 
this patient population is often not well represented in 
clinical trials (Beers et  al. 2014). However, case reports 
suggest that co-occurring medical conditions have a sig-
nificant effect on the disease onset, the disease course, 
treatment response, and outcome (Sami et al. 2015). Dia-
betes mellitus appears to take center stage among these 
disorders.
Recent reports and one meta-analysis have suggested a 
relationship between BD and diabetes mellitus. However, 
these studies could not disentangle the effects of ethnic-
ity, medication use and age, which could have potentially 
confounded the results (Vancampfort et al. 2015). Espe-
cially, the variability in the prevalence of diabetes mellitus 
in the background population has been rarely consid-
ered. Small sample sizes and restricted mean age range 
were the main limitations in most studies. In a system-
atic review, we have attempted to address some of these 
shortcomings. In contrast to previous studies, we have 
focused on large population-based cohort studies from 
diverse ethnic backgrounds with special attention to 
those studies that included the elderly. Then, we reviewed 
the evidence for shared disease mechanisms between BD 
and diabetes mellitus. Finally, we explored the evidence 
for disease-modifying effects and treatment implications.
Methods
Using the combined terms “bipolar disorder” AND 
“elderly” AND “diabetes”, two independent researchers 
have carefully searched the PubMed database for large, 
observational cohort studies with retrospective, cross-
sectional, or prospective design published between Jan-
uary 2009 and December 2015. We found 117 papers; 
7 studies were large cohort studies from diverse popu-
lations (Table  1), and therefore, were suitable for our 
review. Two reviewers independently selected the studies 
and extracted the data in duplicate according to prede-
fined criteria and a study protocol that could be provided 
on request. Studies were included if they were popula-
tion based, contain patients diagnosed with BD based on 
Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition (DSM-IV) or International Classification of 
Diseases (ICD) criteria, and also included patients diag-
nosed with diabetes mellitus. Excluded were studies that 
had excluded elderly patients, studies that were not pop-
ulation based and studies that did not mention the inclu-
sion of patients with diabetes mellitus in addition to BD 
(Fig.  1). Since the number of the identified studies was 
too small and too diverse for meta-analysis, we refrained 
from a statistical analysis. 
Results
Bipolar disorder and diabetes mellitus: is there a 
connection?
The results of the seven large population-based studies 
published between January 2009 and December 2015 
provided strong evidence for a correlation between BD 
and diabetes mellitus (Table  1). When compared to the 
population background, odds ratios for diabetes mel-
litus in patient populations with BD were in the range 
of 1.7–3.2. Reciprocally, BD was more common among 
those with diabetes mellitus compared to the general 
population when adjusted for age and gender (Wändell 
et  al. 2014). A nationwide, population-based longitudi-
nal cohort study found that patients with BD, who had 
no diagnosis of diabetes mellitus at baseline, were more 
likely to begin anti-diabetic medications over the 10-year 
course of the study, even after controlling for gender, 
urbanization, and income (Bai et al. 2013). Across all eth-
nic and racial groups, females seem to have additional 
risk. Glucose and lipids were dysregulated at high rates 
in patients with BD, particularly in women over age 40 
(Wysokinski et  al. 2015), and obesity, a major risk fac-
tor for diabetes mellitus, was highly prevalent (Goldstein 
et al. 2011).
The results of these very large studies are consistent 
with the results of previous literature reviews covering 
smaller studies up to 2012, which found that diabetes 
mellitus occurs up to three times as often among individ-
uals with BD, as it does in the general population (Calkin 
et  al. 2013; Janssen et  al. 2015). However, some studies 
also indicated that metabolic dysfunctions in patients 
with BD are frequently underdiagnosed (Carliner et  al. 
2014; Konz et al. 2014).
Discussion
Bipolar disorder and diabetes mellitus: do these disorders 
share common disease mechanisms?
The results of our study suggest a relationship between 
BD and diabetes mellitus. Therefore, we reviewed the 
supporting evidence for shared disease mechanisms 
based on the broader literature.
A common explanation for the association between 
BD and diabetes mellitus focuses on the diabetogenic 
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side effects of psychotropic medications, but evidence 
is also increasing for a medication-independent asso-
ciation (Foley et  al. 2015). While diabetes mellitus in 
patients with BD has been associated with unintended 
medication effects (Correll et  al. 2015), antipsychotics 
are more strongly linked to incident diabetes mellitus 
than other treatments, such as mood stabilizers and anti-
depressants. Among the antipsychotics, olanzapine and 
clozapine (both second generation antipsychotics) have 
been most strongly linked to diabetes mellitus, because 
they block insulin secretion as antagonists of acetylcho-
line muscarinic 3 receptors in the β-cells of the pancreas 
(Thakurathi and Henderson 2012; Weston-Green et  al. 
2013). A sedentary lifestyle has been claimed as another 
contributing factor to the increased risk of diabetes mel-
litus in patients with BD (Perseghin et  al. 1996; Gomes 
et al. 2013; Janney et al. 2014; Conn et al. 2014). However, 
even after accounting for antipsychotic exposure and 
lifestyle factors, the higher incidence of diabetes mellitus 
among patients with BD remains unexplained, especially 
in treatment-naïve patients (Lilliker 1980; Cassidy et  al. 
1999; Regenold et al. 2002; Ruzickova et al. 2003; McIn-
tyre et al. 2005; Maina et al. 2008; García-Rizo et al. 2014; 
Guha et al. 2014).
The observed association between BD and diabetes 
mellitus has inspired several hypotheses about shared 
disease mechanisms (Calkin et  al. 2013). While some 
researchers have focused on dysregulations of the purine 
metabolism as a common link between energy homeo-
stasis and neuro-regulation (Salvadore et  al. 2010), oth-
ers have proposed elevated cortisol levels related to 
imbalances in the hypothalamic–pituitary–adrenal axis, 
which consequently could result in obesity and derail-
ment of the glucose metabolism (McElroy et  al. 2004). 
A few researchers have hypothesized that insulin resist-
ance in adipose tissue could be mediated by abnormali-
ties in thyroid hormone receptor signaling pathways and 
gene regulation. Imbalances in thyroid hormones have 
long been suspected to be causally related to BD (Iwen 
et al. 2013). A new disease model hypothesizes that thy-
roid hormone receptor-associated protein 3 (Thrap3) 
could activate a diabetogenic gene cascade in adipose 
cells through interaction with cyclin-dependent kinase 
5 (CDK5) leading subsequently to the phosphorylation 
of peroxisome proliferator-activated receptor γ (PPARγ) 
at Ser273 (Choi et al. 2014). An extension of this model 
included sleep abnormalities, which are frequently found 
in patients with psychiatric disorders, as a contributing 
factor to the manifestation of diabetes mellitus (Li et al. 
2013). While thyroid hormone abnormalities have been 
convincingly linked to BD (Bauer et  al. 2014), a causal 
link between thyroid abnormalities, diabetes mellitus, 
and mood symptoms continues to be a focus of intense 
investigations in cell culture and animal models (Wang 
2013).
Increased insulin resistance is commonly considered 
an intermediate phenotype to the manifestation of dia-
betes mellitus. In patients with BD, an alternative path-
omechanism has been explored in the context of the 
metabolic syndrome, a combination of obesity, diabetes 
mellitus, dyslipidemia and hypertension. The metabolic 
syndrome is very common in the general population, 
Literature search in PUBMED of arcles published between January 2009 and December 2015




• age of parcipants 
available in the paper 





• Not a cohort study, not populaon
based
• elderly excluded from the study
• no informaon on the prevalence of 
diabetes mellitus in paents with BD
Fig. 1 Selection process for the inclusion in the systematic review
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but it occurs at even higher rates in patients with BD 
(Fagiolini et  al. 2005). While insulin resistance was not 
increased in patients with BD and metabolic syndrome 
compared to age, gender, and body mass index (BMI)-
matched controls, patients with BD had a reduced capac-
ity to utilize fat as an energy source. This abnormality 
could predispose BD patients to exacerbated weight gain 
and increased risk for diabetes mellitus and cardiovascu-
lar disease (Fleet-Michaliszyn et al. 2008).
Perhaps the most intriguing hypothesis linking BD and 
diabetes mellitus has focused on underlying immune 
dysfunctions paired with a chronic inflammatory state, 
which could confer risk for both BD and diabetes mellitus 
(Leboyer et al. 2012; Hamdani et al. 2013; Sharma et al. 
2014; Rosenblat and McIntyre 2015; Kim et  al. 2015). 
This argument is supported by findings of increased sus-
ceptibility to allergies and elevated pre-inflammatory 
markers in BD and in diabetes mellitus (Goldstein et al. 
2009; Wang et al. 2013; Chen et al. 2014). Oxidative stress 
could also lead to cell damage and apoptosis in the pan-
creas and in the brain, suggesting shared environmental 
risk factors for BD and diabetes mellitus (Reininghaus 
et al. 2014; Wright et al. 2006; Chang and Chuang 2010). 
This disease mechanism has been convincingly dem-
onstrated in rat pancreatic β-cells, in which increased 
β-cell apoptosis was initiated by endoplasmic reticulum 
(ER) stress, mediated by abnormal glycogen synthase 
kinase-3β (GSK-3β) and caspase-3 activity. Valproic acid 
inhibited GSK-3β, which resulted in a cytoprotective 
effect. While this disease mechanism still awaits confir-
mation in patients with BD, the striking results suggest 
abnormal GSK-3β activity as a common link between BD 
and diabetes mellitus supported by a potentially similar 
drug effect of valproic acid on GSK-3β in the pancreas 
and in the brain (Huang et al. 2014).
Bipolar disorder and diabetes mellitus: what are the 
outcomes?
The impacts of BD and diabetes mellitus on each other 
appear to be substantial. Recent work by Calkin et  al. 
found that patients with BD and diabetes mellitus or 
insulin resistance had three times higher risk of hav-
ing a chronic course of BD compared to euglycemic BD 
patients; patients with either type of insulin dysregula-
tion also had three times higher risk of rapid cycling and 
were more likely to be refractory to lithium (Calkin et al. 
2015). In a study of 82,060 patients with diabetes melli-
tus admitted to community hospitals over a 2-year period 
in Washington State, having a serious mental illness sig-
nificantly increased the odds of rehospitalization for non-
mental conditions within 1  month of discharge (odds 
ratio 1.24, 95 % confidence interval 1.07–1.44), even after 
controlling for demographics, medical co-morbidity, and 
index hospitalization (Chwastiak et al. 2014). Among the 
2.2  % with comorbid serious mental illness, 60  % had a 
diagnosis of BD, which was consistent with previous 
studies (Callaghan and Khizar 2010). Other studies con-
firmed that diabetes mellitus increased hospital-based 
mortality in patients with BD (Schoepf and Heun 2014; 
Sylvia et al. 2015).
Worryingly, BD and diabetes mellitus are each inde-
pendently associated with increased risk of dementia and 
reduced cognitive performance (Biessels et  al. 2006; Xu 
et al. 2009; Wu et al. 2013; Zilkens et al. 2014; Depp et al. 
2014). After controlling for vascular risk factors, patients 
with diabetes mellitus show increased evidence for global 
brain atrophy relative to age- and gender-matched con-
trols (Wisse et  al. 2014; Biessels and Reijmer 2014), 
including reduced gray matter density, reduced cerebral 
glucose metabolism in frontotemporal regions (García-
Casares et  al. 2014), increased ventricular volume (De 
Bresser et  al. 2010), and white matter hyper-intensities 
(Reijmer et al. 2011). When compared to euglycemic BD 
patients and non-psychiatric controls, the BD patients 
with insulin resistance or glucose intolerance and dia-
betes mellitus had significantly more neurochemical 
changes in the prefrontal cortex, indicating reduced neu-
ronal health (Hajek et  al. 2015). In one study, patients 
with BD and diabetes mellitus or insulin resistance also 
had significantly smaller hippocampal and cortical vol-
umes than either euglycemic BD patients or controls 
(Hajek et al. 2014).
Separately, each disease is associated with increased 
mortality. Diabetes mellitus is the seventh leading cause 
of death (Center for Disease Control 2014). Among 
adults 18  years and older during the years 2003–2006 
in the US, a diagnosis of diabetes mellitus increased all-
cause mortality about 1.5 times over non-diabetics. For 
BD, a Swedish national cohort study has shown that, rela-
tive to the general population, men and women with BD 
died on average 8.5 and 9.0 years earlier, respectively, and 
for each gender, having BD increased the risk of death by 
twofold (Crump et al. 2013). BD patients have a 20-fold 
greater risk of suicide relative to the general population 
(Jann 2014). Meanwhile, those with BD in addition to 
diabetes mellitus have increased mortality rates of 1.47 
(95  % CI 1.07–2.02) versus those with diabetes mellitus 
but not BD (Vinogradova et al. 2010).
Outlook
Investigations into treatment implications
Both diabetes mellitus and BD are highly refractory: 
less than half of the participants in the National Health 
and Nutrition Examination Survey (NHANES) met gly-
cemic control goals (Koro et  al. 2004). BD patients in 
general have high rates of treatment non-adherence and 
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recurrence. Furthermore, a strong association between 
HbA1c levels and symptoms of depression has been 
described in patients with BD (Bajor et al. 2015; Sajatovic 
et al. 2015b). Because of the difficulties in arresting pro-
gression of diabetes mellitus, achieving lifetime remission 
from BD, and the high stakes involved in both diseases, 
new treatment avenues, especially those that treat the 
potentially shared disease mechanisms of diabetes mel-
litus and BD, are desirable.
In the search for new drug targets, glycogen synthase 
3 (GSK-3) has taken center stage for its known involve-
ment in several pathways linked to both BD and diabetes 
mellitus (Gould et al. 2004; Ronai et al. 2014; Huang et al. 
2014; Iwahashi et  al. 2014). In the rat, lithium, a stand-
ard treatment for BD, reduces the enzyme’s activity in the 
hippocampus and improves memory and learning (Qu 
et al. 2014). Novel GSK-3 inhibitors are now in preclinical 
testing (Datusalia and Sharma 2014; King et al. 2013).
In addition to the GSK-3 pathway, dysregulation of 
noradrenaline signaling could potentially be a shared 
disease mechanism between BD and diabetes mellitus, 
which has led to investigations into prophylactic use of 
noradrenaline modulators (Fitzgerald 2015). With the 
intention to target inflammatory pathways, toll-like 
receptor (TLR)-modifying agents have been tried in dia-
betes mellitus and BD among others (Ladefoged et  al. 
2013; McKernan et al. 2011; Lucas and Maes 2013). Last, 
but not least, treatment with the antidiabetic drug piogl-
itazone as an adjunct to lithium improved symptoms of 
depression in patients with BD even in the absence of 
diabetes mellitus (Zeinoddini et al. 2015).
Bipolar disorder in the elderly: does age of onset hint a 
distinct disease phenotype?
BD in the elderly poses specific challenges for diagnosis 
and treatment (Préville et  al. 2008, 2010; Volkert et  al. 
2013; Sajatovic et  al. 2015a). Although the usual gender 
ratio for BD is 1:1, in elderly patients, more women than 
men receive treatment for BD. Lower overall cognitive 
and executive functioning have been reported in older 
patients with BD compared to both younger patients and 
normal controls in some studies (Tsai et al. 2009; Sheeran 
et  al. 2012). However, not all studies have supported 
these conclusions (Delaloye et al. 2011). Age of onset of 
BD might be a confounding factor.
While BD usually presents with an age of onset dur-
ing adolescence and early adulthood, some individuals 
experience a first episode of mania in and beyond the 5th 
decade of life (Bellivier et al. 2001, 2003; Kennedy et al. 
2005). Most studies on BD in the elderly have not distin-
guished between early-onset and late-onset cases, but 
the evidence for a separate subtype of BD distinguished 
by age of onset is growing, if complex. Late-onset mania 
appears to have a distinctive phenotype, pathophysiol-
ogy, and risk factors (Leboyer et  al. 2005; Vasudev and 
Thomas 2010; Sheeran et  al. 2012; Schouws et  al. 2009, 
2012; Sajatovic et  al. 2005; Sajatovic and Chen 2011; 
Sajatovic et  al. 2015a). In several studies, the late-onset 
group differed in psychiatric comorbidities, includ-
ing lower rates of lifetime alcohol and substance abuse, 
and lower rates of anxiety disorders. In some studies, 
elderly patients with late-onset BD performed particu-
larly worse on tests of psychomotor function and mental 
flexibility compared to those with BD who had an earlier 
age of onset, though elderly patients with BD from both 
groups performed more poorly than age-matched con-
trols (Schouws et  al. 2009, 2012). An increasing burden 
of chronic health problems has been related to the risk 
of late-onset BD including diabetes mellitus, hyperlipi-
demia, and other cardiovascular conditions (Préville et al. 
2010; Sylvia et al. 2015), whereas in BD individuals with 
younger age of onset the risk is much less.
Investigations into the relationship between BD and 
diabetes mellitus have generally focused on all ages of 
patients. Even though late-onset cases of BD were not 
explicitly excluded in most studies, we noticed that few 
studies clearly distinguished between early-onset and 
late-onset cases of BD. However, this distinction could 
be quite relevant to treatment and outcome. Reports that 
particularly focused on late-onset BD and diabetes mel-
litus were sparse, and large studies were non-existing.
Gaps in knowledge and limitations of our study
Even though diabetes mellitus and BD in the elderly are 
growing public health problems, clinical studies on these 
topics are sparse. In general, available studies still suf-
fer from methodological problems including small sam-
ple size, limitations of retrospective chart review, lack of 
standardized measures, overemphasis on inpatients, and 
lack of longitudinal data. Several studies have addressed 
not only the increasing healthcare utilization in elderly 
patients with BD and medical comorbidity, pointing to a 
need for integrated medical and psychiatric care in this 
vulnerable population (Hendrie et  al. 2013), but also to 
existing healthcare disparities for patients with mental 
illness (Gierisch et al. 2014; McGinty et al. 2015).
In our literature review, we have been unable to identify 
published large-scale, multi-center studies on the preva-
lence, the etiology, or the clinical features of late-onset 
BD. To our knowledge, no double-blind, randomized, 
controlled trials of pharmacologic treatments have been 
performed in this specific patient population. Therefore, 
we recommend to increase emphasis on research in BD 
during the late stages of the disease, which could inform 
about the disease course and risk factors across the lifes-
pan. It is hoped that this knowledge will not only assist in 
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enhancing services and improving outcomes, but it might 
also lead to the discovery of potentially new pathophysi-
ological pathways and risk factors for BD and diabetes 
mellitus, as well as to novel treatments and interventions.
Conclusions and recommendations
Increasing evidence supports the association between BD 
and diabetes mellitus and suggests shared risk factors and 
disease mechanisms. This public health problem deserves 
focused attention, especially in the elderly, to improve 
diagnosis, treatment and outcome. A stronger integration 
of medical and psychiatric care could help prevent the 
negative effects of these co-occurring disorders on the 
long-term outcome of patients with BD. Therefore, we 
recommend to increase research efforts on late-life BD 
and diabetes mellitus to better understand the complex 
relationship that exists between these disorders. A better 
understanding of risk factors in BD and diabetes mellitus 
could lead to novel treatment approaches, early interven-
tion and prevention.
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